- Home
- NGVT vs CNTA Comparison
NGVT vs CNTA Comparison
Compare NGVT & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGVT
- CNTA
- Stock Information
- Founded
- NGVT 1964
- CNTA 2020
- Country
- NGVT United States
- CNTA United Kingdom
- Employees
- NGVT N/A
- CNTA N/A
- Industry
- NGVT Major Chemicals
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- NGVT Industrials
- CNTA Health Care
- Exchange
- NGVT Nasdaq
- CNTA Nasdaq
- Market Cap
- NGVT 2.0B
- CNTA 2.3B
- IPO Year
- NGVT N/A
- CNTA 2021
- Fundamental
- Price
- NGVT $57.78
- CNTA $17.01
- Analyst Decision
- NGVT Buy
- CNTA Strong Buy
- Analyst Count
- NGVT 2
- CNTA 10
- Target Price
- NGVT $55.00
- CNTA $30.56
- AVG Volume (30 Days)
- NGVT 344.1K
- CNTA 1.2M
- Earning Date
- NGVT 08-04-2025
- CNTA 08-12-2025
- Dividend Yield
- NGVT N/A
- CNTA N/A
- EPS Growth
- NGVT N/A
- CNTA N/A
- EPS
- NGVT N/A
- CNTA N/A
- Revenue
- NGVT $1,324,800,000.00
- CNTA $15,000,000.00
- Revenue This Year
- NGVT N/A
- CNTA N/A
- Revenue Next Year
- NGVT $4.72
- CNTA N/A
- P/E Ratio
- NGVT N/A
- CNTA N/A
- Revenue Growth
- NGVT N/A
- CNTA 118.88
- 52 Week Low
- NGVT $28.49
- CNTA $9.60
- 52 Week High
- NGVT $57.87
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- NGVT 73.95
- CNTA 54.91
- Support Level
- NGVT $53.79
- CNTA $17.01
- Resistance Level
- NGVT $56.89
- CNTA $18.14
- Average True Range (ATR)
- NGVT 1.76
- CNTA 0.81
- MACD
- NGVT 0.49
- CNTA -0.10
- Stochastic Oscillator
- NGVT 98.82
- CNTA 51.08
About NGVT Ingevity Corporation
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.